Abstract:Parkinson's disease (PD), multiple system atrophy (MSA) and Dementia with Lewy bodies (DLB) represent pathologically similar, progressive neurodegenerative disorders characterized by the pathological aggregation of the neuronal protein α-synuclein. PD and DLB are characterized by the abnormal accumulation and aggregation of α-synuclein in proteinaceous inclusions within neurons named Lewy bodies (LBs) and Lewy neurites (LNs), whereas in MSA α-synuclein inclusions are mainly detected within oligodendrocytes named glial cytoplasmic inclusions (GCIs). The presence of pathologically aggregated α-synuclein along with components of the protein degradation machinery, such as ubiquitin and p62, in LBs and GCIs is considered to underlie the pathogenic cascade that eventually leads to the severe neurodegeneration and neuroinflammation that characterizes these diseases. Importantly, α-synuclein is proposed to undergo pathogenic misfolding and oligomerization into higher-order structures, revealing self-templating conformations, and to exert the ability of "prion-like" spreading between cells. Therefore, the manner in which the protein is produced, is modified within neural cells and is degraded, represents a major focus of current research efforts in the field. Given that α-synuclein protein load is critical to disease pathogenesis, the identification of means to limit intracellular protein burden and halt α-synuclein propagation represents an obvious therapeutic approach in synucleinopathies. However, up to date the development of effective therapeutic strategies to prevent degeneration in synucleinopathies is limited, due to the lack of knowledge regarding the precise mechanisms underlying the observed pathology. This review critically summarizes the recent developed strategies to counteract α-synuclein toxicity, including those aimed to increase protein degradation, to prevent protein aggregation and cell-to-cell propagation, or to engage antibodies against α-synuclein and discuss open questions and unknowns for future therapeutic approaches.

Role of Ubiquitin–Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance

In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons

SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation

Autophagy and Its Comprehensive Impact on ALS

The Role of α-Synuclein in Etiology of Neurodegenerative Diseases

Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy

α-Synuclein ubiquitination – functions in proteostasis and development of Lewy bodies

Initiation and propagation of α-synuclein aggregation in the nervous system

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity

Monitoring α-synuclein ubiquitination dynamics reveals key endosomal effectors mediating its trafficking and degradation

Crosstalk Between the Proteasome System and Autophagy in the Clearance of Α-Synuclein

Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways

The role of polo-like kinases 2 in the proteasomal and lysosomal degradation of alpha-synuclein in neurons

Role of Α-Synuclein in Microglia: Autophagy and Phagocytosis Balance Neuroinflammation in Parkinson’s Disease

The Roles of Post-translational Modifications on Α-Synuclein in the Pathogenesis of Parkinson’s Diseases

Protein Quality Control Pathways at the Crossroad of Synucleinopathies

α-Synuclein pathology as a target in neurodegenerative diseases

α-Synuclein amyloid fibril directly binds to LC3B and suppresses SQSTM1/p62-mediated selective autophagy

Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease

Preventing α-synuclein aggregation: The role of the small heat-shock molecular chaperone proteins